TEMTempus AI Inc
$53.76
$1.44
(2.75%)
EarningsAug 7
Mkt Cap$9.39B
Vol258,385.00
Fundamentals
16 Million People, One Underserved Disease: The AI Imaging Push to Close the Congenital Heart Gap
16 Million People, One Underserved Disease: The AI Imaging Push to Close the Congenital Heart Gap 16 Million People, One Underserved Disease: The AI Imaging Push to Close the Congenital Heart Gap PR Newswire TORONTO, ON, June 16, 2026 Issued on behalf of Ventripoint Diagnostics Ltd.As the number of...
PR Newswire
Tempus Announces Multi-Center Validation of AI-Enabled ECG Model for Predicting Atrial Fibrillation Risk Published in Heart Rhythm
Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine, today announced publication of successful multi-site validation of its software, which received U.S. Food and Drug Administration clearance in 2024 for predicting the one-year risk of...
Business Wire
Genetics in Medicine Open Study Demonstrates How Ambry Genetics ExomeReveal RNA Testing Can Improve Diagnostic Clarity in Exome Testing
Ambry Genetics, a leader in clinical genomic testing, and a wholly owned subsidiary of Tempus AI, Inc. (NASDAQ: TEM), announced peer-reviewed research demonstrating the potential for variant-specific RNA testing to provide greater clarity for patients who receive a variant of uncertain significance...
Business Wire
Great News: This Explosive Healthcare Stock Could Be a Powerful Artificial Intelligence Winner
Tempus AI (NASDAQ: TEM) is trying to build more than a diagnostics business. Its growing healthcare data platform, artificial intelligence tools, FDA progress, and pharma partnerships could create meaningful upside if the company can scale profitably. But the stock already reflec...
Nasdaq News: Markets
Tempus to Present at the Goldman Sachs 47th Annual Global Healthcare Conference
Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine, today announced that it will participate in the Goldman Sachs 47th Annual Global Healthcare Conference. Tempus Founder and CEO Eric Lefkofsky will participate in a fireside chat at 2:00...
Business Wire
Why Is Tempus (TEM) Down 11.2% Since Last Earnings Report?
Tempus (TEM) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Zacks
Tempus Launches Open-Source Digital Pathology Consortium, Names Yale New Haven Health and Leading Cancer Center as Founding Members
Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine, Yale New Haven Hospital (YNHH) and Memorial Sloan Kettering Cancer Center (MSK) today announced the launch of a digital pathology IMS Open-Source Consortium (IMS Consortium). Designed to...
Business Wire
H.C. Wainwright Maintains Buy Rating on Tempus AI (TEM) Following Strong Revenue Growth
H.C. Wainwright Maintains Buy Rating on Tempus AI (TEM) Following Strong Revenue Growth...
Yahoo! Finance: News
Tempus Announces the Upcoming Clinical Availability of Its First Whole-Genome Sequencing Assay, xH
Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine, today announced the upcoming clinical availability of xH, a next-generation sequencing (NGS) test that uses a whole-genome sequencing (WGS) approach for the detection of actionable...
Business Wire
Tempus Unveils the Next-Generation of Lens, Expanding its Agentic AI Platform for Oncology Drug Development
Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine, today announced the launch of the next-generation of Lens, its pioneering agentic AI platform designed to accelerate drug development and research. This evolution seamlessly connects Tempus...
Business Wire
<
1
2
...
>
Advertisement|Remove ads.
Latest TEM News
View16 Million People, One Underserved Disease: The AI Imaging Push to Close the Congenital Heart Gap
PR Newswire
Tempus Announces Multi-Center Validation of AI-Enabled ECG Model for Predicting Atrial Fibrillation Risk Published in Heart Rhythm
Business Wire
Genetics in Medicine Open Study Demonstrates How Ambry Genetics ExomeReveal RNA Testing Can Improve Diagnostic Clarity in Exome Testing
Business Wire
Advertisement|Remove ads.